NCT05292391View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

March 19, 2024

Study Completion Date

March 19, 2024

Conditions
Schistosomiasis
Interventions
BIOLOGICAL

Sm-p80

The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.

BIOLOGICAL

Sm-p80 + GLA-SE

Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.

Trial Locations (1)

98101-1466

Kaiser Permanente Washington Health Research Institute, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH